Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study
British Journal of Dermatology2017Vol. 177(4), pp. 1033–1042
Citations Over TimeTop 10% of 2017 papers
Robert Bissonnette, Thomas A. Luger, Diamant Thaçi, D. Toth, I. Messina, R. You, Adriana Guana, T. Fox, C. Papavassilis, I. Gilloteau, Ulrich Mrowietz
Abstract
Secukinumab 300 mg FI sustained high responses and improved quality of life with no new safety concerns through 3 years.
Related Papers
- → Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial(2017)64 cited
- → Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept(2017)33 cited
- → Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study(2017)30 cited
- → PASI (Psoriasis Area and Severity Index) in the evaluation of the clinical manifestations of psoriasis(2016)14 cited
- 건선 환자에서 Cyclosporine 치료 효과와 관련된 인자에 대한 후향적 연구(2021)